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To the Editor:
We thank Edouard Reizine et al for their interest in our work and
for their thoughtful comments. As mentioned in our article, and in
accordance with the current literature, the hepatobiliary phase
(HBP) of Gd-BOPTA does not appear to be reliable to differentiate
between hepatocellular adenoma (HCA) and focal nodular hyperpla-
sia (FNH).1 Several remarks mentioned in the letter will be
addressed.
T1-Weighted Hyperintensity Before Contrast
Injection
As suggested by our findings, difficulties concerning HBP may be
partially due to precontrast hyperintensity of the lesion. The let-
ter’s authors argue that this is probably due to underlying steatosis,
which will reveal the lesion as hyperintense on fat-saturated
images. We agree with this and have previously highlighted this
potential diagnostic dilemma, particularly in inflammatory HCAs
after injection of Gd-BOPTA.2 However, in contrast to previously
published data from Reizine et al, we found that surrounding
steatosis is not the only cause of hyperintensity on precontrast
images.3 Intrinsic hyperintensity is demonstrably an additional
source of false-positive iso/hyperintensity in HBP. This can easily
be appreciated on in-phase T1-weighted images and is probably
due to residue from microscopic bleeds. Upon reanalysis of our
data, we found that hyperintensity on precontrast images was due
to steatosis in 29/41 cases (71%), intrinsic hyperintensity in 7/41
cases (17%), and was attributable to both causes in 5/41 cases
(12%). More important, intrinsic hyperintensity is a very reliable
sign for HCA, as it is never seen in FNH (because FNHs simply
do not bleed).4
Enhancement vs. Pseudoenhancement
We agree with the authors that real uptake versus pseudoenhancement
(due to surrounding steatosis or intrinsic hyperintensity) is an
important issue when relying on the HBP alone; even more so
since uptake is related to glutamine synthetase expression and b-
catenin positivity.5 Tumors that show noticeable uptake in HBP
include FNH, inflammatory HCAs, b-catenin HCAs, and some
well-differentiated hepatocellular carcinomas (HCCs).6 It should
also be noted that in most cases FNH can be easily differentiated
from other lesions (which may require closer observation) based
on additional radiological and clinical parameters.
LLCER Method
The LLCER (lesion-to-liver contrast enhancement ratio) method, as pro-
posed by Roux et al7 and mentioned by the authors of the letter, is an
elegant approach to objectify whether iso/hyperintensity in HBP is due
to uptake of contrast. This method takes into account the intensity of
the lesion before contrast injection. Theoretically, if the LLCER is above
a certain threshold the uptake is real, thus favoring FNH, or in some rare
cases, inflammatory HCA, b-catenin HCA, or HCC. Unfortunately, the
benefits of LLCER currently remain within the confines of theory, as we
have shown that the method is poorly reproducible, and most important,
does not provide reliable cutoffs.8 These problems are due to the fact that
the patient is removed from the bore after the dynamic phase, to return
only after around 1 hour. In contrast to computed tomography (CT),
absolute values cannot be determined in magnetic resonance imaging
(MRI) and repositioning of the patient has a very disruptive effect on
absolute measurements. One way to potentially overcome this problem is
by comparing relative measurements before and 1 hour after contrast
injection. However, this approach also appears to have limited reliability,
based on our previous validation study.8 At the present time we are
forced to conclude that this method needs further refinement and is
therefore not yet suitable for use in daily clinical practice.
Inflammatory HCA
The final remarks of Reizine et al relate to the fact that the sub-
typing of inflammatory HCA is less feasible when using Gd-EOB-
DTPA. This is indeed correct and is due to the poorer reliability of
the venous phase when using this contrast agent. However, clinical
practice has taught us that the most important role of MRI is to dif-
ferentiate HCA from FNH in young females using oral contracep-
tives. Whether a lesion is in fact an inflammatory HCA can provide
useful additional information to predict b-catenin positivity (ie,
b-cat-positive inflammatory HCAs), and malignant potential.9 Once
radiological diagnosis confirms an inflammatory HCA, one could
opt for biopsy to exclude b-catenin positivity, although current
guidelines do not discuss this option at the present time.10
In conclusion, measuring lesion contrast uptake would be an
attractive tool for differentiating HCAs and FNHs; however, we
think the current status does not allow us to use this method in daily
clinical practice.
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